Carbergoline for Antipsychotic Induced Hyperprolactinemia.

Condition(s) studied

Investigational drug(s) / intervention(s)

Cabergoline (Dopamine Agonist): This intervention will use cabergoline for antipsychotic induced hyperprolactinemia.

Placebo: Placebo + standard care

Study summary

The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia. The main question it aims to answer :

Is the severity of positive and negative symptoms affected by the use of cabergoline?

Researchers will compare cabergolin to placebo to see if positive and negative symptoms are equel in both groups.

Participants will, in a blinded manor, take either placebo tablets or cabergoline for 12 weeks. The severity of positive and negative symptoms will be evaluated before and after the intervention in both groups.

Eligibility

Primary outcome measure(s)

• Total score on the PANSS (Positive and Negative Syndrome Scale) — At end of intervention, i.e. 12 weeks from baseline.
  The primary outcome is the total score of the PANSS in absolute numbers at the end of intervention (12 weeks) comparing the placebo group with the intervention group (cabergoline).

Trial sites (1)

More Zealand University Hospital trials in Denmark